|
| Press Releases |
|
 |
|
| Saturday, August 24, 2024 |
|
|
Ministry of Health, Labour and Welfare in Japan Approves Partial Change Application for Moderna's COVID-19 mRNA Vaccine Targeting SARS-COV-2 Variant JN.1 |
| Moderna, Inc. (NASDAQ:MRNA) today announced that it has received approval from the Ministry of Health, Labour and Welfare (MHLW) in Japan for a partial change application for an updated formulation of its COVID-19 mRNA vaccine Spikevax, targeting the SARS-CoV-2 variant JN.1. more info >> |
|
| Tuesday, March 26, 2024 |
|
|
Moderna Achieves Positive Interim Results from Phase 3 Trial of Next-Generation COVID-19 Vaccine |
| Moderna, Inc. (NASDAQ:MRNA) today announced that mRNA-1283, the Company's next-generation COVID-19 vaccine, has successfully met the primary endpoints of its Phase 3 clinical trial, demonstrating a higher immune response against SARS-CoV-2 when compared to mRNA-1273.222, Moderna's licensed COVID-19 vaccine. more info >> |
|
| Monday, December 11, 2023 |
|
|
Moderna Reviews its Environmental, Social and Governance (ESG) Progress and Ambitions at Second ESG Investor Event |
| more info >> |
|
| Wednesday, July 5, 2023 |
|
|
Moderna Announces Global Regulatory Submissions for Its Respiratory Syncytial Virus (RSV) Vaccine, MRNA-1345 |
| Moderna, Inc. (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today provided an update on regulatory submissions for mRNA-1345, a vaccine for the prevention of RSV-associated lower respiratory tract disease (RSV-LRTD) and acute respiratory disease (ARD) in adults aged 60 years or older. more info >> |
|
| Wednesday, May 3, 2023 |
|
|
Moderna Announces Establishment of an Enterprise Solutions Hub and Commercial Operations in The Philippines |
| Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced plans to establish an Enterprise Solutions Hub in the Philippines. The Moderna Enterprise Solutions Hub will provide business services across the Asia Pacific region, where Moderna currently has operations in six markets. Moderna also plans to establish commercial operations in the Philippines. more info >> |
|
| Tuesday, September 13, 2022 |
|
|
Indonesia's Bio Farma ready to produce IndoVac Covid-19 vaccines |
| PT Bio Farma, the holding company for state-owned pharmaceutical companies in Indonesia, announced a new milestone in manufacturing IndoVac, a Covid-19 vaccine brand it has developed since November 2021. more info >> |
|
| Friday, September 9, 2022 |
|
|
Indonesian pharmaceutical Bio Farma ready to produce IndoVac Covid-19 vaccines |
| PT Bio Farma, the holding company for state-owned pharmaceutical companies in Indonesia, announced a new milestone in the manufacturing process of IndoVac, a Covid-19 vaccine brand it has developed since November 2021. more info >> |
|
| Tuesday, July 19, 2022 |
|
|
Therapeutic Goods Administration Grants Provisional Approval for Moderna's COVID-19 Vaccine in Children Aged Six Months to Five Years |
| Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the Therapeutic Goods Administration (TGA) in Australia has granted provisional registration for the use of Moderna's mRNA COVID-19 vaccine, Spikevax, in a two-dose series of 25 ug per dose for active immunization to prevent COVID-19 caused by SARS-CoV-2 in children aged 6 months to 5 years. more info >> |
|
| Thursday, February 17, 2022 |
|
|
Therapeutic Goods Administration of Australia Authorizes Moderna's Covid-19 Vaccine in Children (6-11 Years) |
| Moderna, Inc., (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the Therapeutic Goods Administration (TGA) in Australia has granted provisional registration for the use of Moderna's mRNA COVID-19 vaccine, Spikevax, in a 50 ug dose, two-dose series, for active immunization to prevent COVID-19 caused by SARS-CoV-2 in children aged 6-11 years. more info >> |
|
| Wednesday, February 16, 2022 |
|
|
Moderna Announces Plan to Expand Footprint in Asia with Four Additional Subsidiaries |
| Moderna, Inc., (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced plans to expand its commercial network across Asia with the addition of four new subsidiaries in Malaysia, Taiwan, Singapore, and Hong Kong. This expansion comes as the Company continues to scale up the manufacturing and distribution of its COVID-19 vaccine and future mRNA vaccines and therapeutics. more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
GMG Launches First to Market Multi Language Global Graphene Enhanced Product Range for Distributors
Sept 17, 2025 19:39 HKT/SGT
|
|
|
Casa Minerals Inc Announces Advanced Ground IP Survey at the Arsenault Project
Sept 17, 2025 18:09 HKT/SGT
|
|
|
Definitive agreement to implement a joint mine plan between Los Bronces and Andina copper mines
Sept 17, 2025 18:57 JST
|
|
|
Open Doors to the Asian Market: Seoul Bio Hub-Celltrion Launches 'Global Open Innovation' for U.S. Startups 
Sept 17, 2025 17:30 HKT/SGT
|
|
|
Anti-MTBR (microtubule binding region) Tau Antibody Etalanetug Granted FDA Fast Track Designation
Sept 17, 2025 18:20 JST
|
|
|
HKTDC welcomes 2025 Policy Address
Sept 17, 2025 17:01 HKT/SGT
|
|
|
Honda Announces New Electric Motorcycle "Honda WN7" in Europe
Sept 17, 2025 17:46 JST
|
|
|
Ultraman Card Game Original Illustration of "Alien Metron" By Manga Artist Yukinobu Tatsu to be Included in the Upcoming Booster Pack Release
Sept 17, 2025 12:56 HKT/SGT
|
|
|
Professor Lin Xiang Xiong Hosts Landmark Art Exhibition and Peace Prize Ceremony in Paris
Sept 17, 2025 11:44 HKT/SGT
|
|
|
How Not to Lose the Billion Dollars You Didn't Know You Had-Groundbreaking Guide to Protecting Family Fortunes
Sept 17, 2025 10:00 HKT/SGT
|
|
|
Karbon-X Corp. Files Year-End Financial Results
Sept 17, 2025 09:08 HKT/SGT
|
|
|
TruMerit Adds Two More Global Credentials for Rehabilitation Care Workers
Sept 17, 2025 08:00 HKT/SGT
|
|
|
EASD 2025 | HighTide Therapeutics Announces Oral Presentation of Phase 3 Data in Patients with Type 2 Diabetes
Sept 17, 2025 9:00 JST
|
|
|
Second Blue Magic Netherlands Event Set for November 18
Sept 17, 2025 00:30 HKT/SGT
|
|
|
U.S. Polo Assn. Celebrates Sport and Style as Official Apparel Sponsor of the 2025 Engel & Volkers Berlin Maifeld Polo Cup
Sept 16, 2025 19:00 HKT/SGT
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
